Mucormycosis News and Research

RSS

Scientists discover kidney-friendly antifungal that evades resistance

In this investigation, researchers produced powerful antifungals of the polyene class without nephrotoxicity.

9 Nov 2023

Understanding the mechanisms behind rising antifungal drug resistance

In a recent study, researchers addressed the issue of the rise of antifungal drugs-resistant infections and the advent of multidrug-resistant fungal pathogens.

19 Jul 2023

How did the COVID-19 pandemic impact the fungal infection hospitalization rates?

Researchers examined hospitalizations for fungal infections during the coronavirus disease 2019.

9 Jun 2023

Light-activated nanoscale drills can combat infectious fungi

That stubborn athlete's foot infection an estimated 70% of people get at some point in their life could become much easier to get rid of thanks to nanoscale drills activated by visible light.

1 Feb 2023

An unprecedented list of health-threatening fungi released by the WHO

The WHO fungal priority pathogens list ranks pathogens that pose a serious risk of morbidity and mortality in humans.

27 Oct 2022

Novel antifungal medications urgently needed to control COVID-19-associated fungal infections

Every day we inhale thousands of potentially pathogenic fungal spores, but our immune system simply eliminates them.

9 Sep 2022

High prevalence of fungal secondary infections among COVID-19 patients

Researchers analyze literature to explore the frequency of secondary fungal infections among COVID-19 patients.

2 Aug 2022

Cow dung likely behind black fungus epidemic in India

Cow dung, widely used as a fuel and in rituals in India, is likely behind an epidemic of black fungus that killed or maimed thousands of patients treated in the country for COVID-19 in 2021, say medical researchers.

4 Apr 2022

COVID-19 associated mucormycosis cases in India

India continues to grapple with the coronavirus disease (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). To date, the country has reported over one million new cases for the past 28 days.

31 Aug 2021

Study connects hyperglycemia and prolonged cloth mask use to COVID-19-associated mucormycosis risk

A new study conducted in India identifies the role of high blood sugar levels in predisposing patients to mucormycosis infection.

1 Aug 2021

Black fungus complicates India's COVID pandemic

India faces a global health crisis as the number of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections reaches over 23.7 million. As India's health system buckles with increased admissions and a lack of resources, another health threat has emerged.

13 May 2021

Fungal disease is emerging among hundreds of COVID-19 patients in India, shows study

Authorities scramble to provide drugs to treat a fungal disease affecting India's COVID-19 patients. A fungal disease called mucormycosis is emerging among hundreds of COVID-19 patients in India, placing further strain on hospitals already at breaking point.

12 May 2021

Post-mortem study of dead COVID-19 patients finds lung damage and blood clots

A new post-mortem study of patients who have died from COVID-19 found severe damage to the lungs and signs of blood clotting in major organs.

20 Aug 2020

Researchers identify specific pathways involved in development of mucormycosis

Research published today in the journal, Nature Communications, provides new insights into the evolution of Mucorales fungi, which cause a fatal infection in ever-increasing segments of patient population, and several molecular pathways that might be exploited as potential therapeutic or diagnostic targets.

22 Jul 2016

Department of Health issues statement on CDC preliminary report regarding infection cluster at UPMC

Today, Pennsylvania Secretary of Health Karen Murphy issued a statement on the Centers for Disease Control (CDC) preliminary report on an infection cluster found at the University of Pittsburgh Medical Center (UPMC).

23 Dec 2015

Astellas reports topline results from isavuconazole Phase 3 study in candidemia and other invasive Candida infections

Astellas today announced topline results from the Phase 3 ACTIVE study evaluating the efficacy and safety of intravenous (IV) and oral isavuconazole, commercially known as CRESEMBA (isavuconazonium sulfate), under development for adults with candidemia and other invasive Candida infections.

30 Jul 2015

FDA approves Astellas' CRESEMBA for treatment of invasive aspergillosis, invasive mucormycosis

Astellas today announced that the U.S. Food and Drug Administration has approved its New Drug Application (NDA) for the use of CRESEMBA (isavuconazonium sulfate), the prodrug for isavuconazole, for patients 18 years of age and older in the treatment of invasive aspergillosis and invasive mucormycosis (also known as zygomycosis).

8 Mar 2015

New NIH grant to support development of rapid method for diagnosing mucormycosis

Speed is essential in treating deadly mucormycosis fungal infections, but a quick diagnosis is difficult because no routine blood test exists.

19 Feb 2015

UM SOM launches ‘Program in Lung Healing’ to develop treatments for acute respiratory failure

University of Maryland School of Medicine (UM SOM) Dean E. Albert Reece, MD, PhD, MBA, and Jeffrey A. Rivest, MS, President and Chief Executive Officer of University of Maryland Medical Center (UMMC), today announced the official launch of a new "Program in Lung Healing," that will further the School's position as a national leader in research, education and clinical innovation for acute ailments of the lung and respiratory system.

9 Feb 2015

Solgar voluntarily recalls ABC Dophilus Powder

Solgar, Inc., of Leonia, NJ, is voluntarily recalling ABC Dophilus Powder. The recall was initiated, out of an abundance of caution, because the product was found to contain Rhizopus oryzae, which may cause Mucormycosis.

16 Nov 2014